主要人参皂苷Rg1对哺乳动物的长寿和体力活力的影响很少报道。为了研究摄取Rg1的大鼠的寿命、肿瘤和自发运动活动，我们将138只Wistar大鼠随机分成2组：对照组（N = 69）和Rg1组（N = 69）。自6个月龄开始，每天口服Rg1（0.1毫克/千克）直到自然死亡。在5、14、21和28个月龄时，通过视频跟踪和双能X射线吸收测量身体构成和炎症标记物，测量自发性运动。两组之间在寿命（对照组：706天；Rg1组：651天，p = 0.77）和肿瘤发生率（对照组：19％；Rg1组：12％，p = 0.24）方面没有显着差异。对照组的运动距离在21个月龄时下降了约60％，伴随着TNF-α的降低（p = 0.01）和IL-10的上升（p = 0.02）。然而，Rg1组的运动距离在21个月龄时仍保持在控制组的约50％以上（p = 0.01），且TNF-α减少和IL-10增加的程度更大。整个观察期间，两组的血糖、胰岛素和身体构成（骨骼、肌肉和脂肪比例）相似。这项研究的结果表明，终身Rg1摄取可以推迟晚年的年龄相关性体力下降，这种改善与炎症调节有关。在长寿和肿瘤形成方面，Rg1的显着影响并未观察到。本文版权属于The Korean Society of Ginseng，由Elsevier B.V.提供出版服务。

Effects of the major ginsenoside Rg1 on mammalian longevity and physical vitality are rarely reported.To examine longevity, tumor, and spontaneous locomotor activity in rats consuming Rg1.A total of 138 Wistar rats were randomized into 2 groups: control (N = 69) and Rg1 (N = 69). Rg1 (0.1 mg/kg per day) were orally supplemented from 6 months of age until natural death. Spontaneous mobility was measured by video-tracking together with body composition (dual energy x-ray absorptiometry) and inflammation markers at 5, 14, 21, and 28 months of age.No significant differences in longevity (control: 706 days; Rg1: 651 days, p = 0.77) and tumor incidence (control: 19%; Rg1: 12%, p = 0.24) were observed between the two groups. Movement distance in the control group declined significantly by ∼60% at 21 months of age, together with decreased TNF-α (p = 0.01) and increased IL-10 (p = 0.02). However, the movement distance in the Rg1 group was maintained ∼50% above the control groups (p = 0.01) at 21 months of age with greater magnitudes of TNF-α decreases and IL-10 increases. Glucose, insulin, and body composition (bone, muscle and fat percentages) were similar for both groups during the entire observation period.The results of the study suggest a delay age-dependent decline in physical vitality during late life by lifelong Rg1 consumption. This improvement is associated with inflammatory modulation. Significant effects of Rg1 on longevity and tumorigenesis were not observed.© 2021 The Korean Society of Ginseng. Publishing services by Elsevier B.V.